Short answer
CASTLE BIOSCIENCES INC (CSTL) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $103M (up 23.9% year over year) with net income of −$4M.
Q3 2026 key financials · XBRL
- Revenue
- $103M
- +23.9% YoY · −0.6% QoQ
- Net income
- −$4M
- −718.4% YoY · −99.0% QoQ
- Operating margin
- -2.7%
- EPS (diluted)
- −$0.14
- −600.0% YoY · −133.3% QoQ
Source: XBRL data from the CASTLE BIOSCIENCES INC (CSTL) Q3 2026 10-Q on SEC EDGAR. USD.
CASTLE BIOSCIENCES INC Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $102.9M, up 23.9% YoY from $83.0M
- Gross margin 74.7% vs 74.7% YoY; operating loss $2.7M vs $6.8M
- Best segment: non-dermatologic revenue $55.0M, up $20.5M; TissueCypher volume up 47%
- Worst segment: dermatologic revenue $47.9M, down $0.6M; DecisionDx-SCC affected by lost Medicare coverage
- Cash $78.0M vs $116.7M at year-end; nine-month operating cash flow $12.8M, capital expenditures $28.6M
Risk Factors
- No material changes overall from the 2025 10-K, aside from updates described below
- Accumulated deficit $245.0 million at September 30, 2026, versus $224.3 million at December 31, 2025
- Medicare reimbursement discontinuation for DecisionDx-SCC continued reducing its revenue contribution in 2026
- New geopolitical risk: February 2026 U.S.-Iran conflict and Strait of Hormuz disruption threaten energy supplies and shipping routes
- Macroeconomic risk: inflation increased personnel and laboratory supply costs, potentially limiting liquidity and capital access
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CASTLE BIOSCIENCES INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.